ProCE Banner Activity

CE

Clinical Updates on Inflammatory Bowel Disease: Need to Know Information for Managed Care Professionals

Video

Pharmacists: 1.50 contact hours (0.15 CEUs)

Released: February 07, 2022

Expiration: February 07, 2023

No longer available for credit.

Share

Additional Information

Program Medium

This program has been made available online.

Activity Description

Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease (CD) and ulcerative colitis (UC). IBD confers a significant disease burden for patients globally in terms of distressing symptoms, hospitalizations and surgeries, cancer risk, financial costs, and quality of life. The expanding number of IBD treatments becoming available and the complexity of IBD treatment and monitoring decisions create uncertainty for healthcare professionals (HCPs) caring for patients with moderate to severe disease.

As medication therapy experts, pharmacists can aid in both the clinical and financial management of IBD. The goal of this activity is to improve the knowledge and competence of pharmacists about evidence-based recommendations for the treatment of moderate to severe UC and CD, therapeutic drug monitoring for biologic therapy, clinical data on emerging therapies, and strategies for pharmacists to optimize patient care.

Target Audience

The target audience is pharmacists, including managed care pharmacists, and clinical pharmacists who care for patients with inflammatory bowel diseases. In addition, the target audience includes pharmacy directors, chief pharmacy officers, health plan administrators, and other stakeholders in managed care pharmacy.

Learning Objectives

After completing the activity, participants should be able to:
  • Describe evidence-based recommendations for induction and refractory treatment of moderate to severe ulcerative colitis and Crohn’s disease.
  • Discuss therapeutic drug monitoring (TDM) and how to determine treatment changes based on TDM results for biologics.
  • Evaluate clinical data on emerging therapies for IBD.
  • Identify strategies for optimizing patient care with pharmacists, including medication adherence counseling, assisting with medication access, and adverse effect assessments.

Faculty

Timothy Edminster, PharmD
Clinical Pharmacist
Division of Gastroenterology, Hepatology and Nutrition
University of Florida
Gainesville, FL

Stacy S. Tse, PharmD, BCPS
Clinical Pharmacist
Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center
Mount Sinai Hospital
New York, NY

CE Accreditation

Release Date: January 12, 2022
Expiration Date: February 7, 2023
Pharmacists
ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-008-H01-P has been assigned to this home study, knowledge-based activity. This activity is approved for 1.5 contact hour (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
 

Disclosure

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. Faculty disclosures will be provided prior to the start of the CE activities. Stacy S. Tse, PharmD, BCPS, does not have any relevant conflicts of interest to report. Timothy Edminster, PharmD, does not have any relevant conflicts of interest to report.

Funding

This activity is supported by an educational grant from Ferring Pharmaceuticals. 
The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.